AGOURA HILLS, Calif., March 18, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc., (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-Beta antisense drug candidate, today provided an update on its rapid antiviral response program against...
·Last patient completes last visit in the six-month, placebo-controlled part of study ·18 patients have continued into open-label extension ·Top-line results from placebo-controlled part of study still expected in Q2 2020 Saniona (SANION.ST), a clinical stage...
Basel, 19 March 2020- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced we are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced...
SOUTH SAN FRANCISCO, Calif.–(Business Wire)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company is working with the U.S. Food & Drug Administration (FDA) to initiate a randomized, double-blind,...
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company is working with the U.S. Food & Drug Administration (FDA) to initiate a randomized, double-blind,...
Basel, 19 March 2020- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced we are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced...
Email
Text